University of Maryland (UM) Ventures and Breethe, Inc. announced today that Breethe, an early-stage, Baltimore-based medical device company, has obtained exclusive rights to University of Maryland, Baltimore (UMB) intellectual property (IP) for the development of a wearable, portable blood pump oxygenator that will function as an artificial lung system for patients suffering from respiratory failure and cardiopulmonary collapse. Faculty at the University of Maryland School of Medicine (UM SOM) developed the core licensed technology, with Breethe also obtaining important supporting technology co-owned by UMB and University of Maryland, Baltimore County (UMBC) as part of the license agreement. The Breethe team plans to leverage the technology to bring the first wearable ‘out-of-hospital’ artificial lung system to market. UMB has made a $100,000 investment in Breethe through UM Ventures.